# PPD clinical research business of Thermo Fisher Scientific

> PPD clinical research business of Thermo Fisher Scientific is a VC fund backing Health Care. See 6 investments, check sizes, portfolio and contact details…

- Type: VC Fund
- Location: Wilmington, United States
- Total investments: 6
- Last investment: Oct 2021
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/ppd
- X (Twitter): http://twitter.com/ppdcro
- Website: http://www.ppd.com
- Facebook: http://www.facebook.com/PPDCRO

PPD clinical research business of Thermo Fisher Scientific is a VC fund in Wilmington focused on Health Care and Clinical Trials. PPD is a global contract research organization (CRO) providing discovery, development, and post-approval services as well as compound partnering programs. Their clients and partners include pharmaceutical, biotechnology, medical device, academic, and government organizations.PPD applies innovative technologies, therapeutic expertise, and a firmcommitment to quality to help customers bend the cost and time curve of drug development to provide life-changing therapies that improve health.

## Contacts

5 contacts available for PPD clinical research business of Thermo Fisher Scientific. Shizune tracks 8 team members at PPD clinical research business of Thermo Fisher Scientific. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ppd?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 33% |
| Clinical Trials | 2 | 33% |
| Messaging | 1 | 17% |
| Biotechnology | 1 | 17% |
| Medical Device | 1 | 17% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Venture - Series Unknown | 2 | 33% |
| Series C | 1 | 17% |
| Series D | 1 | 17% |
| Post-IPO Equity | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Brent Reed | Director of IT | 0 | — |
| Claire Nickols | Director, Project Oversight, Haematology & Oncology, Global Project Management | 0 | — |
| Duu-Gong Wu | Senior Director, Regulatory and Technical Advisors, Global Regulatory Affairs, | 0 | — |
| Jeffrey Carcillo | Vice President, Enterprise Data | 0 | — |
| Kimberly Kasprowicz | Sr. Clinical Team Manager | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Science 37 | Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representativepatient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials. | $200M | Post-IPO Equity | Oct 07, 2021 |  |
| Medable | Medable provides a global decentralized trial platform that streamlines design, recruitment, retention, and data quality, replacing siloed systems with integrated digital tools, data, and interfaces to accelerate trial execution. The platform connects patients, sites, and clinical trial teams to improve patient access, experience, and outcomes. Itis now used by leading biopharma sponsors and clinical research organizations worldwide and has been used for trials in 30+ countries and 26 languages.It was founded in 2015 and is headquartered in Palo Alto, California. | $78M | Series C | Apr 15, 2021 |  |
| Medable | Medable provides a global decentralized trial platform that streamlines design, recruitment, retention, and data quality, replacing siloed systems with integrated digital tools, data, and interfaces to accelerate trial execution. The platform connects patients, sites, and clinical trial teams to improve patient access, experience, and outcomes. Itis now used by leading biopharma sponsors and clinical research organizations worldwide and has been used for trials in 30+ countries and 26 languages.It was founded in 2015 and is headquartered in Palo Alto, California. | $91M | Series C | Nov 19, 2020 |  |
| Science 37 | Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representativepatient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials. | $40M | Venture - Series Unknown | Aug 20, 2020 |  |
| Medable | Medable provides a global decentralized trial platform that streamlines design, recruitment, retention, and data quality, replacing siloed systems with integrated digital tools, data, and interfaces to accelerate trial execution. The platform connects patients, sites, and clinical trial teams to improve patient access, experience, and outcomes. Itis now used by leading biopharma sponsors and clinical research organizations worldwide and has been used for trials in 30+ countries and 26 languages.It was founded in 2015 and is headquartered in Palo Alto, California. | $25M | Venture - Series Unknown | May 04, 2020 |  |
| Science 37 | Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representativepatient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials. | $35M | Series D | Jan 03, 2019 |  |

6 of 6 investments shown.

## Co-investors
- [GSR Ventures](https://shizune.co/investors/profile/gsr-ventures-management) — VC Fund, 3 deals together
- [Sapphire Ventures](https://shizune.co/investors/profile/sapphire-ventures) — VC Fund, 3 deals together
- [Streamlined](https://shizune.co/investors/profile/streamlined-ventures) — VC Fund, 3 deals together
- [dRx Capital](https://shizune.co/investors/profile/drx-capital) — VC Fund, 2 deals together
- [Glynn Capital Management](https://shizune.co/investors/profile/glynn-capital-management) — VC Fund, 2 deals together
- [LifeSci Venture Partners](https://shizune.co/investors/profile/lifesci-venture-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

## FAQ

### What does PPD clinical research business of Thermo Fisher Scientific invest in?

PPD clinical research business of Thermo Fisher Scientific invests primarily in Health Care, Clinical Trials and Messaging startups, most often at Venture - Series Unknown and Series C stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact PPD clinical research business of Thermo Fisher Scientific?

Public channels for PPD clinical research business of Thermo Fisher Scientific include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at PPD clinical research business of Thermo Fisher Scientific?

The team at PPD clinical research business of Thermo Fisher Scientific includes Brent Reed (Director of IT), Claire Nickols (Director, Project Oversight, Haematology & Oncology, Global Project Management) and Duu-Gong Wu (Senior Director, Regulatory and Technical Advisors, Global Regulatory Affairs,), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co